3:37 PM
 | 
Dec 14, 2018
 |  BC Extra  |  Company News

Amgen pulls out of Advaxis immunotherapy deal

Advaxis Inc. (NASDAQ:ADXS) will continue to enroll patients in a Phase I trial of its ADXS-NEO program despite Amgen Inc. (NASDAQ:AMGN) pulling out of a 2016 deal to develop the immunotherapy. Advaxis...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >